annualreport.gsk.comAnnual Report 2023 | GSK

Company Back to main Company Company Purpose, strategy and culture Outstanding people Company Outstanding people Working together My GSK story Innovating together 2022 Innovating together 2021 GSK at a glance History and heritage Board of directors and leadership team Board information Governance Company Governance Committees Shareholders Sarbanes-Oxley Act 2002 Compliance Policy positions Codes, standards and reports FEATURED SECTION Our purpose, strategy and culture FEATURED SECTION Outstanding peopleInnovation Back to main Innovation Innovation Research and development approach Pipeline Therapeutic areas Innovation Therapeutic areas Infectious diseases HIV Respiratory/immunology Oncology Technologies Clinical trials at GSK Innovation Clinical trials at GSK Provision of unlicensed medicines for unmet medical needs Data transparency Diversity in clinical trials Partnering with GSK Innovation Partnering with GSK Supported studies R&D locations SPOTLIGHT ON Behind the science magazine Featured section Partnering with GSKProducts Back to main Products Products Our product areas Products A-Z SPOTLIGHT ON Innovation FEATURED WEBSITE GSKPro for healthcare professionalsResponsibility Back to main Responsibility Responsibility Access Global health and health security Responsibility Global health and health security Global health Health security Using our science for global health Improving access to healthcare Environment Responsibility Environment Climate Freshwater Land Oceans Atmosphere Materials and waste Diversity, equity and inclusion Ethical standards Responsibility Ethical standards Working with third parties Public policy and patient advocacy Human rights Use of animals Engaging with healthcare professionals Product governance Charitable Investments ESG resources Responsibility ESG resources ESG reports archive FEATURED SECTION Diversity equity and inclusion SPOTLIGHT ON Our policy positionsInvestors Back to main Investors Investors Why invest in GSK? Quarterly results Financial reports Investors Financial reports Annual Report 2023 Corporate reports archive Environmental, social and governance Speeches and presentations Science publications Events calendar Dividend and share price Investors Dividend and share price GSK share price Share price calculators (GBp/USD) Dividend calculators (GBp/USD) Dividend calendar Analyst consensus Stock exchange announcements Investors Stock exchange announcements London (RNS) London (RNS) inside information New York (SEC) Sign up for announcements Shareholder information Investors Shareholder information Manage your shares Annual General Meeting General Meeting Annual Governance Meeting Corporate sponsored nominee service Our ADR programme Asset reunification - ProSearch Share scam alert Privacy notice for ordinary shareholders FAQs Corporate actions Investors Corporate actions Consumer Healthcare Demerger Consumer Healthcare Joint Venture Agreement to acquire TESARO Debt investors Feedback Investor contacts SPOTLIGHT ON Press releases SPOTLIGHT ON Our pipelineMedia Back to main Media Media Press releases Media contacts Conferences Media library Our response to the situation in Ukraine Our response to the crisis in Israel and Gaza Our social media RSS feeds FEATURED SECTION Behind the science magazine SPOTLIGHT ON ConferencesCareers Back to main Careers Careers Search jobs Featured careers Careers Featured careers A career in Data Life at GSK Careers Life at GSK What’s your angle? Experienced professionals Careers Experienced professionals Business Operations Engineering at GSK Manufacturing and supply Marketing and sales Research and development Experienced professionals Research and development Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS) Genomic sciences Technology Early talent Careers Early talent Kickstart your career Apprentice programmes Work experience, placements and internships Future leaders graduate programme Early talent Future leaders graduate programme Business operations Engineering Manufacturing Operations, Quality & Supply Chain Marketing and sales Research and development Technology Manufacturing Sciences & Technology Post graduate opportunities Veterans Our global and regional hubs How we hire Careers How we hire Frequently asked questions Fraudulent internet recruitment activities FEATURED SECTION Outstanding people FEATURED SECTION Diversity equity and inclusionHealthcare professionals Healthcare professionals Contact us Contact us Home Investors Financial reports Annual Report 2023 Annual Report 2023 At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive. ANNUAL REPORT Download the full report, individual sections or visit iXBRL viewer Annual Report 2023 Strategic report 2023 Responsible business 2023 Governance and Remuneration report 2023 Financial statements 2023 Investor information 2023 Cautionary statement 2023 Annual Report 2023 iXBRL viewer Annual Report 2023 ESEF 2023 Annual Report on Form 20-F We are a focused biopharma company with strong momentum and big ambitions We prevent and treat disease with vaccines, specialty & general medicines We prevent and treat disease with vaccines, specialty & general medicines We focus on the science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/immunology and oncology). Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. We’re confident in our future We’re confident in our future With our strong momentum and improving outlook for sustained growth through the decade, we’re confident in our ability to deliver human health impact at scale, worldwide. We get ahead of issues that matter for society and company sustainability We get ahead of issues that matter for society and company sustainability We’re committed to getting ahead of issues that matter for society and for the sustainability of our company, too – including access to healthcare, diversity, equity and inclusion, and the health of our planet. We’re sector leaders in ESG performance, making an impact on some of society’s most urgent challenges. Our purpose puts our people at the heart of our success Our purpose puts our people at the heart of our success Core to our Ahead Together ambition is to make GSK a place where talented people thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we deliver for our patients, shareholders and GSK people. 2023 performance and key performance indicators Financial performance We delivered strong performance and upgraded our growth outlooks. Broad-based performance drove sales, profits and earnings growth. Group turnover £30.3bn AER 3% CER 5% (Ex-COVID-19 AER 12% CER 14%) Vaccines turnover £9.9bn AER 24% CER 25% Specialty Medicines turnover £10.2bn AER -9% CER -8% General Medicines turnover £10.2bn AER 1% CER 5% Total operating profit £6.7bn AER 5% CER 10% Adjusted operating profit £8.8bn AER 8% CER 12% (Ex-COVID-19 AER 12% CER 16%) Research and development We continued to strengthen the late-stage pipeline with organic R&D delivery and targeted business development, supporting future growth. £10bn sales of products launched or with major lifecycle innovation expansion in the last five years 4 major approvals including in infectious diseases, HIV and oncology 18 assets in phase III/registration 71 assets in the pipeline 6 major business development deals 12 at least 12 major product launches planned from 2025 Responsible business We continue to be recognised for our environmental and sustainability leadership. Our ESG Performance Rating is on track based on...